Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter study conducted at approximately 20 sites. Each patient
will inject GA daily for 6 weeks utilizing an autoject 2 device to determine overall
injection satisfaction.